Dr. Massimo Cristofanilli, MD is an oncologist in Chicago, Illinois. He is currently licensed to practice medicine in Illinois and Pennsylvania.
He is an expert in the research and management of hormone-receptor positive metastatic breast cancer and IBC. He is a pioneer in liquid biopsy including CTCs and ctDNA research and clinical applications. He leads the Precision Medicine program at the Lurie Cancer Center, NU aimed at application of NGS and omics for patients' care.
Education & Training
Patient-Centered Specialty Practice Recognition Program
National Committee for Quality Assurance, 2014-2017
Lifetime Achievement Award for Ethics and Creativity in Medical Research
Giovan Giacomo Giordano NIAF, 2012
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer.
Current treatment options in oncology
Gerratana, L., Davis, A. A., Shah, A. N., Lin, C., Corvaja, C., Cristofanilli, M.
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jiang, Z.,Li, W.,Hu, X.,Zhang, Q.,Sun, T.,Cui, S.,Wang, S.,Ouyang, Q.,Yin, Y.,Geng, C.,Tong, Z.,Cheng, Y.,Pan, Y.,Sun, Y.,Wang, H.,Ouyang, T.,Gu, K.,Feng, J.,Wang, X.,Wang, S.,Liu, T.,Gao, J.,Cristofanilli, M.,Ning, Z.,Lu, X.
Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.
Yanez, B.,Bouchard, L. C.,Cella, D.,Sosman, J. A.,Kircher, S. M.,Mohindra, N. A.,Cristofanilli, M.,Penedo, F. J.
Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib
Clin Breast Cancer
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M
Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor positive breast cancer
Clin Cancer Res
Jeselsohn R, Yelensky R, Buchwalter G, Frampton GM, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo A, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross J, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt SJ, Come SE, Pusztai L, Stephens PJ, Brown M, Miller VA
CytoDyn Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
FinancialBuzz · September 09, 2019
...our Phase 1b/2 trial using leronlimab in treatment-naïve mTNBC patients is under the supervision of Massimo Cristofanilli, M.D., professor of Medicine in the Division of Hematology/Oncology at Northwestern University Fein...
Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer Under Emergency IND, Launching CytoDyn into Oncology
Let Life Happen · August 30, 2019
...to the Phase 1b/2 trial with leronlimab for treatment-naïve mTNBC patients under the supervision of Massimo Cristofanilli, M.D., who is an expert in translational research treatment of patients with mTNBC and professor of...
CytoDyn Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer
FinancialBuzz · August 08, 2019
...our Phase 1b/2 trial using leronlimab in treatment-naïve mTNBC patients is under the supervision of Massimo Cristofanilli, M.D. professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinb...